Yale University has developed the intellectual property behind Anteros and was first in-licenced by BMS and later authorised to Anteros. BioMotiv CEO Dr Satish Jindal said: “Anteros Pharmaceuticals
The post Bristol-Myers Squibb, BioMotiv launch new biotechnology firm Anteros Pharmaceuticals appeared first on Pharmaceutical Business review.